David Tat1,2, Stacey A Kenfield2,3, Janet E Cowan2, Jeanette M Broering2, Peter R Carroll2, Erin L Van Blarigan2,4, June M Chan2,4. 1. Duke University School of Medicine, Durham, North Carolina. 2. Department of Urology, University of California San Francisco, San Francisco, California. 3. Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts. 4. Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California.
Abstract
BACKGROUND: High-fat dairy, particularly whole milk, in healthy men may increase risk of aggressive prostate cancer. However, data are limited regarding dairy after prostate cancer diagnosis. METHOD: We conducted a prospective study among 1334 men with non-metastatic prostate cancer in the Cancer of the Prostate Strategic Urologic Research Endeavor. Men answered a food frequency questionnaire in 2004-2005 (median 2 years after diagnosis) and were followed until 2016 for recurrence, defined as: prostate cancer death, bone metastases, biochemical recurrence, or secondary treatment. Multivariate Cox proportional hazards regression was used to calculate hazards ratios (HR) and 95% confidence intervals (CI) for associations between whole and low-fat milk; total, high-fat, and low-fat dairy; and other dairy items and risk of recurrence. RESULTS: During a median follow-up of 8 years, we observed 137 events. Men who consumed >4 servings/week versus 0-3 servings/month of whole milk had an 73% increased risk of recurrence (HR: 1.73; 95%CI: 1.00, 2.98; P-value = 0.04). Body mass index (BMI) modified the association (P-interaction = 0.01). Among men with a BMI ≥27 kg/m2 , >4 servings/week versus 0-3 servings/month of whole milk was associated with a 3-fold higher risk of recurrence (HR: 2.96; 95%CI: 1.58, 5.54; P-value < 0.001). No association was seen in men with BMI <27 kg/m2 . Low-fat milk and other dairy foods were not associated with recurrence. CONCLUSION: In conclusion, whole milk consumption after prostate cancer diagnosis was associated with increased risk of recurrence, particularly among very overweight or obese men. Men with prostate cancer who choose to drink milk should select non-fat or low-fat options.
BACKGROUND: High-fat dairy, particularly whole milk, in healthy men may increase risk of aggressive prostate cancer. However, data are limited regarding dairy after prostate cancer diagnosis. METHOD: We conducted a prospective study among 1334 men with non-metastatic prostate cancer in the Cancer of the Prostate Strategic Urologic Research Endeavor. Men answered a food frequency questionnaire in 2004-2005 (median 2 years after diagnosis) and were followed until 2016 for recurrence, defined as: prostate cancer death, bone metastases, biochemical recurrence, or secondary treatment. Multivariate Cox proportional hazards regression was used to calculate hazards ratios (HR) and 95% confidence intervals (CI) for associations between whole and low-fat milk; total, high-fat, and low-fat dairy; and other dairy items and risk of recurrence. RESULTS: During a median follow-up of 8 years, we observed 137 events. Men who consumed >4 servings/week versus 0-3 servings/month of whole milk had an 73% increased risk of recurrence (HR: 1.73; 95%CI: 1.00, 2.98; P-value = 0.04). Body mass index (BMI) modified the association (P-interaction = 0.01). Among men with a BMI ≥27 kg/m2 , >4 servings/week versus 0-3 servings/month of whole milk was associated with a 3-fold higher risk of recurrence (HR: 2.96; 95%CI: 1.58, 5.54; P-value < 0.001). No association was seen in men with BMI <27 kg/m2 . Low-fat milk and other dairy foods were not associated with recurrence. CONCLUSION: In conclusion, whole milk consumption after prostate cancer diagnosis was associated with increased risk of recurrence, particularly among very overweight or obesemen. Men with prostate cancer who choose to drink milk should select non-fat or low-fat options.
Authors: Panagiota N Mitrou; Demetrius Albanes; Stephanie J Weinstein; Pirjo Pietinen; Philip R Taylor; Jarmo Virtamo; Michael F Leitzmann Journal: Int J Cancer Date: 2007-06-01 Impact factor: 7.396
Authors: F B Hu; E Rimm; S A Smith-Warner; D Feskanich; M J Stampfer; A Ascherio; L Sampson; W C Willett Journal: Am J Clin Nutr Date: 1999-02 Impact factor: 7.045
Authors: Matthew R Cooperberg; David J Pasta; Eric P Elkin; Mark S Litwin; David M Latini; Janeen Du Chane; Peter R Carroll Journal: J Urol Date: 2005-06 Impact factor: 7.450
Authors: Mary K Downer; Julie L Batista; Lorelei A Mucci; Meir J Stampfer; Mara Meyer Epstein; Niclas Håkansson; Alicja Wolk; Jan-Erik Johansson; Ove Andrén; Katja Fall; Sven-Olof Andersson Journal: Int J Cancer Date: 2017-02-22 Impact factor: 7.396
Authors: Song-Yi Park; Suzanne P Murphy; Lynne R Wilkens; Daniel O Stram; Brian E Henderson; Laurence N Kolonel Journal: Am J Epidemiol Date: 2007-10-08 Impact factor: 4.897
Authors: Kerry N L Avery; Jenny L Donovan; Rebecca Gilbert; Michael Davis; Pauline Emmett; Liz Down; Steven Oliver; David E Neal; Freddie C Hamdy; J Athene Lane Journal: Cancer Causes Control Date: 2013-03-22 Impact factor: 2.506
Authors: June M Chan; Stacey A Kenfield; Rebecca E Graff; Crystal S Langlais; Erin L Van Blarigan; Claire H Pernar; Meir J Stampfer; Edward L Giovannucci; Lorelei A Mucci Journal: Br J Cancer Date: 2022-08-26 Impact factor: 9.075
Authors: Hanna E Röhnisch; Cecilie Kyrø; Anja Olsen; Elin Thysell; Göran Hallmans; Ali A Moazzami Journal: BMC Med Date: 2020-07-23 Impact factor: 8.775